Aardvark Therapeutics, Inc. (NASDAQ:AARD) Receives Average Rating of "Buy" from Brokerages

Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) has been given a consensus recommendation of "Buy" by the four analysts that are currently covering the company, Marketbeat.com reports. Four investment analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $31.25.

AARD has been the subject of a number of recent research reports. HC Wainwright started coverage on Aardvark Therapeutics in a research note on Monday. They set a "buy" rating and a $40.00 price target for the company. Bank of America upped their price objective on shares of Aardvark Therapeutics from $22.00 to $26.00 and gave the stock a "buy" rating in a report on Thursday, March 27th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $50.00 price target on shares of Aardvark Therapeutics in a research report on Tuesday, April 1st. Morgan Stanley assumed coverage on shares of Aardvark Therapeutics in a research note on Monday, March 10th. They issued an "overweight" rating and a $29.00 target price on the stock. Finally, Wall Street Zen cut shares of Aardvark Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, June 14th.

Hedge Funds Weigh In On Aardvark Therapeutics

A number of large investors have recently modified their holdings of AARD. Walleye Capital LLC bought a new position in Aardvark Therapeutics during the first quarter worth $88,000. Goldman Sachs Group Inc. bought a new stake in shares of Aardvark Therapeutics during the 1st quarter valued at $153,000. Adage Capital Partners GP L.L.C. acquired a new stake in Aardvark Therapeutics during the first quarter worth about $1,878,000. Braidwell LP acquired a new position in Aardvark Therapeutics during the first quarter valued at approximately $3,755,000. Finally, Cormorant Asset Management LP bought a new stake in shares of Aardvark Therapeutics during the 1st quarter worth $6,009,000.

Aardvark Therapeutics Stock Performance

Shares of AARD opened at $13.39 on Monday. Aardvark Therapeutics has a 1-year low of $4.88 and a 1-year high of $19.58. The business has a 50-day moving average of $10.93.

Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.01).

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.